Kasabach-Merritt phenomenon: A single centre experience

European Journal of Haematology

Volumn 84, Issue 2, 2010, Pages 97-104

  Ryan, Clodagh ^a   Price, Vicotria ^b   John, Philip ^c   Mahant, Sanjay ^c   Baruchel, Sylvain ^c   Brandão, Leonardo ^c   Blanchette, Victor ^c   Pope, Elena ^c   Weinstein, Miriam ^c  

^a MERCY UNIVERSITY HOSPITAL   (Ireland)

^b DALHOUSIE UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Consumptive coagulopathy; Embolisation; Haemangioma; Kasabach Merritt phenomenon; KMP

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; AMINOCAPROIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FIBRINOGEN; MEPREDNISONE; PENTOXIFYLLINE; PREDNISONE; TICLOPIDINE; TRANEXAMIC ACID; VINCRISTINE;

ACNE; ARTIFICIAL EMBOLISM; BLEEDING; BLOOD ANALYSIS; CLINICAL ARTICLE; DEATH; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FIBRINOGEN BLOOD LEVEL; FLU LIKE SYNDROME; GROWTH RETARDATION; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOFIBRINOGENEMIA; INFANT; KASABACH MERRITT SYNDROME; LETHARGY; MALE; MICROANGIOPATHY; MONOTHERAPY; MORBIDITY; MORTALITY; OSTEOPENIA; PATHOLOGIC FRACTURE; PEDIATRIC HOSPITAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFANT; INFANT, NEWBORN; INTERFERONS; MALE; PENTOXIFYLLINE; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 74049125939     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01370.x     Document Type: Review

References (31)

1. Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002 24 : 459 462.
2. El-Dessouky M, Azmy AF, Raine PAM, et al. Kasabach-Merritt syndrome. J Pediatr Surg 1988 23 : 109 111.
3. Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura; report of a case. Arch Pediatr Adolesc Med 1940 59 : 1063 1070.
4. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Meritt syndrome do not have 'true' hemangiomas. J Pediatr 1997 4 : 631 640.
5. Hall GW, Bolton Maggs P, Hann I. Kasabach-Merritt syndrome: caveats of diagnosis and management. Curr Paediatr 2000 10 : 72 8.
6. Pampin C, Devillers A, Treguier C, et al. Intramural consumption of indium-111-labelled platelets in a child with splenic hemangioma and thrombocytopenia. J Pediatr Hematol Oncol 2000 22 : 256 258.
7. Seo SK, Suh JC, Na GY, et al. Kasabach-Merritt syndrome: identification of platelet trapping in tufted angioma by immunochemistry technique using monoclonal antibody to CD61. Pediatr Dermatol 1999 16 : 392 394.
8. Esterly NB. Kasabach-Merritt syndrome in infants. J Am Acad Dermatol 1983 8 : 504 513.
9. Enjolras O, Riche M, Merland J, et al. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 1990 85 : 491 498.
10. Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001 112 : 851 862.
11. Ozsoylu S, Irken G, Gurgey A. High dose intravenous methylprednisolone for Kasabach-Merritt syndrome. Eur J Pediatr 1989 148 : 403 495.
12. Gidding CE, Kellie SJ, Kamps WE, et al. Vincristine revisited. Crit Rev Oncol Hematol 1999 29 : 267 287.
13. Chang E, Boyd A, Nelson C, et al. Successful treatment of infantile hemangiomas with Interferon-a-2b. J Pediatr Hematol Oncol 1997 19 : 237 244.
14. Ezekowitz R, Mulliken J, Folkman J. Interferon alfa-2a therapy for life threatening hemangioma of infancy. N Engl J Med 1992 326 : 1456 1463.
15. Hatley R, Sabio H, Howell C, et al. Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt syndrome with alpha-interferon. J Pediatr Surg 1993 28 : 1356 1357.
16. Barlow CF, Priebe RA, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998 132 : 527 530.
17. Worle H, Maass E, Kohler B, et al. Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication. Eur J Pediatr 1999 158 : 344.
18. Sato Y, Frey EE, Wicklund B, et al. Embolization therapy in the management of infantile hemangioma with Kasabach-Meritt syndrome. Pediatr Radiol 1987 17 : 503 504.
19. Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Meritt phenomenon in 41 patients. J Am Acad Dermatol 2000 42 : 225 235.
20. Stanley P, Gomperts E, Woolley MM. Kasabach-Merritt syndrome treated by therapeutic embolization with polyvinyl alcohol. Am J Pediatr Hematol Oncol 1986 8 : 308 311.
21. Mitsuhashi N, Furuta M, Sakurai H, et al. Outcome of radiation therapy for patients with Kasabach-Meritt syndrome. Int J Radiat Oncol Biol Phys 1997 39 : 467 473.
22. De la Hunt M. Kassabach-Merritt syndrome: dangers of interferon and successful treatment with pentoxifylline. J Pediatr Surg 2006 41 : E29 31.
23. De Prost Y, Teillac D, Bodemer C, et al. Successful treatment of Kasabach Merritt syndrome with pentoxifylline. J Am Acad Dermatol 1991 25 : 854 855.
24. Walter J, North P, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002 33 : 295 303.
25. Blei F. Basic science and clinical aspects of vascular abnormalities. Curr Opin Pediatr 2005 17 : 501 509.
26. Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangioma. J Clin Invest 2001 107 : 745 752.
27. Kleinman ME, Blei F, Gurtner GC. Circulating endothelial progenitor cells and vascular anomalies. Lymphat Res Biol 2005 4 : 234 239.
28. Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood 2004 103 : 1373 1375.
29. Hammerling G, Gans R. Vascular integration of endothelial progenitors during multistep tumor progression. Cell Cycle 2006 5 : 509 511.
30. Verhaul HM, Panigraphy D, Flynn E, et al. Treatment of Kasabach-Merritt syndrome with pegylated recombinant human growth and development factor in mice: elevated platelet counts, prolonged survival and tumour growth inhibition. Pediatr Res 1999 46 : 562 565.
31. Baruchel S, Stempak D. Low dose metronomic chemotherapy; myth or truth. Onkologie 2006 29 : 305 307.